

1 **SUPPLEMENTAL MATERIAL**

2

3 **Atrial Fibroblast-Derived Macrophage Migration Inhibitory Factor Promotes Atrial**
4 **Macrophage Accumulation in Postoperative Atrial Fibrillation**

5

6 Joshua A. Keefe^{1,2}, Jose Alberto-Navarro Garcia^{1,2}, Shuai Zhao^{1,2}, Mihail G. Chelu^{1,3,4},
7 Xander H. T. Wehrens^{1,2,3,5,6,7}

8

9 ¹Cardiovascular Research Institute, ²Department of Integrative Physiology, ³Department
10 of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, TX 77030,
11 USA.

12 ⁴Texas Heart Institute at Baylor St. Luke's Medical Center, Houston, TX 77030, USA.

13 ⁵Department of Neuroscience, ⁶Department of Pediatrics (Division of Cardiology), ⁷Center
14 for Space Medicine, Baylor College of Medicine, Houston, TX 77030, USA.

15

16 **Running title:** MIF Recruits Macrophages in Postoperative AF

17

18 **Correspondence to:** Xander Wehrens, M.D., Ph.D., Cardiovascular Research Institute,
19 Baylor College of Medicine, BCM335, One Baylor Plaza, Houston, TX 77030. Email:
20 wehrens@bcm.edu; ORCID: 0000-0001-5044-672X

21 **METHODS**

22

23 Study approval: All animal studies were performed according to protocols approved by
24 the Institutional Animal Care and Use Committee of Baylor College of Medicine (AN-9166)
25 conforming to the Guide for the Care and Use of Laboratory Animals published by the US
26 National Institutes of Health (Publication no. 85-23, revised 1996).

27

28 Sex as a biological variable: All mice included in this study were 12-15 week-of-age,
29 C57BL/6J background purchased from the Jackson Laboratory (Bar Harbor, ME), and
30 equal numbers of male and female mice were used when possible. Controls consisted of
31 wild-type littermates. All studies and analyses were performed in a blinded manner when
32 possible.

33

34 Mouse open heart surgery was performed as previously described (1). Briefly, mice were
35 given preprocedural analgesia with extended-release buprenorphine (Wedgewood
36 Connect, San Jose, CA) at 1.0 mg/kg at least one hour prior to surgery. Mice were
37 intubated and ventilated (tidal volume 150 μ L, respiratory rate of 175 breaths/minute).
38 Anesthesia was maintained using 2.5% v/v isoflurane (11695067771, Covetrus, Houston,
39 TX) in 100% oxygen, and body temperature was maintained at $37.0\pm 0.5^{\circ}\text{C}$ by rectal
40 thermometer (Rodent Surgical Monitor+, Indus Instruments, Webster, TX). The thoracic
41 cavity was exposed through the 2nd intercostal space. Bi-atrial pericardiectomy and cross-
42 clamping of the thoracic aorta for 20 seconds were performed. For the sham (Sh)
43 procedure, endotracheal intubation and skin and pectoral muscle dissection were

44 performed, but the thoracic cavity was not entered. MIF inhibitor, 4-IPP, was administered
45 intraperitoneally at 50 mg/kg once a day from the time of surgery through postoperative
46 day two (2).

47

48 Programmed Electrical Stimulation (PES) was performed as previously described (1, 3).

49 Mice were anesthetized using 2% v/v isoflurane/oxygen, and a 1.1F octopolar catheter
50 (EPR-800, Millar, Houston, TX) was inserted into the right atrium and ventricle through

51 the right jugular vein. The octopolar catheter leads were connected to an external

52 stimulator (STG3008, MultiChannel Systems, Reutlingen, Germany), and the signals

53 were acquired using IOX2.4 acquisition software (Emka Technologies, Sterling, VA).

54 Proper catheter positioning was verified by electrogram waveforms and response to atrial

55 pacing (3). All PES protocols were performed at 1.75% v/v isoflurane/oxygen and rectal

56 temperature between $37.0 \pm 0.5^\circ\text{C}$. AF inducibility was determined via decremental pacing

57 by performing a series of 2s bursts with a pulse width of 1 ms. The starting BCL was 40

58 ms and was decreased by 2 ms after each 2s burst until a BCL of 20 ms was reached.

59 Burst pacing was performed in triplicate for each mouse, and AF was defined as the

60 presence of an irregularly irregular rhythm without discernable P waves for at least 1

61 second on at least two out of three atrial burst pacing protocols (1).

62

63 Single-cell RNA sequencing (scRNAseq): Atrial non-myocytes were isolated after PES

64 studies by mechanical and enzymatic digestion using 450 U/mL collagenase II (C2-28,

65 Sigma-Aldrich, St. Louis, MO), 125 U/mL collagenase XI (C7657, Sigma-Aldrich, St.

66 Louis, MO), 60 U/mL DNase (D45131VL, Sigma-Aldrich, St. Louis, MO), and 60 U/mL

67 hyaluronidase (5030-9954, Bio-Rad, Hercules, CA), dissolved in Hanks Balanced Salt
68 Solution (HBSS) with 1.26 mM Ca²⁺ and 0.9 mM Mg²⁺. Atrial tissue pieces were placed
69 in prewarmed digestion buffer in a water bath at 37.0°C and triturated every 10 minutes
70 for 30 minutes. The digestion reaction was quenched using 10% FBS in HBSS without
71 Ca²⁺ and Mg²⁺. Cells were filtered through a 70-µm filter and spun at 340 x g for 7 minutes
72 at 4°C. Cells were resuspended in RBC lysis buffer for 5 minutes on ice and then spun at
73 340 x g for 7 minutes at 4 °C. Cells were resuspended in 5% FBS in HBSS without Ca²⁺
74 and Mg²⁺. Single cell suspensions were loaded onto a 10X Genomics Chromium
75 Controller using 10X Single Cell RNA reagents v3.1 (4). DNA libraries were generated
76 following the Chromium scRNA-seq v3.1 protocol. DNA libraries were sequenced using
77 a Next Generation Sequencer NovaSeq 6000 (~30,000 reads per cell). All scRNA-seq,
78 library preparation, and sequencing were performed at the Baylor College of Medicine
79 Single Cell Genome Sequencing Center. To analyze scRNAseq data, raw FASTQ files
80 were demultiplexed and aligned to mouse reference genome (mm10) using Cell Ranger
81 v7.1.0. Count files from Cell Ranger were imported into Seurat for quality control and
82 subsequent analyses (4, 5). Briefly, cells were filtered by >200 unique genes, <10,000
83 number of RNA molecules, <30% mitochondrial genes, <3% Malat1 expression, and
84 <0.01% Hba expression. Seurat objects were merged, normalized, and integrated using
85 FindIntegrationAnchors. Cell clusters were identified by dimensionality reduction with
86 principal component analysis (RunPCA) and shared nearest neighbor (SNN) analysis and
87 visualized on UMAP plots. Differentially regulated cell-cell communication pathways were
88 analyzed using CellChat v1.6.1 (6).

89

90 Western blotting: Immediately following PES on postoperative day three, mouse whole
91 atrial tissue was snap-frozen in liquid nitrogen. 70 μ L of RIPA lysis buffer containing 1%
92 CHAPS, Phos-STOP (4906837001, Sigma-Aldrich, St. Louis, MO) and complete mini
93 protease inhibitor cocktail (4693124001, Sigma-Aldrich, St. Louis, MO), 20mM sodium
94 fluoride (NaF), 1mM Na_3VO_4 was added, and atrial tissue was homogenized with steel
95 beads using a homogenizer (Tissue Lyser LT, Qiagen, Germantown, MD) at 50-Hz for 5
96 minutes. Samples were sonicated and centrifuged at 14,000 rpm for 20 mins at 4°C.
97 Supernatants were collected as protein lysates, and protein concentration was measured
98 using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA). 60 μ g
99 protein was loaded into each well of a 10-12% polyacrylamide gel run at 100 volts.
100 Proteins were transferred onto a 0.45- μ m polyvinylidene fluoride (PVDF) membrane for
101 1.5-h at 100 Volts at room temperature in ice cold Tris-Glycine transfer buffer containing
102 20% methanol. Membranes were blocked for 1-h at room temperature (catalog #20-314,
103 Genesee Scientific, El Cajon, CA) and incubated overnight at 4°C with primary antibodies
104 (F4/80, Cell Signaling Technology, catalog #70076, clone D2S9R, 1:1000; GAPDH,
105 Proteintech, catalog #60004, clone 1E6D9, 1:5000; CXCR2, Proteintech, catalog #19538,
106 1:1000) diluted in blocking buffer (catalog #20-314, Genesee Scientific, El Cajon, CA).
107 Membranes were washed 3 times with TBST (0.1% tween-20) for 10 minutes each and
108 incubated with secondary antibody (goat anti-mouse, Invitrogen #A32729, 1:10,000; goat
109 anti-rabbit, Invitrogen #A32735, 1:10,000) for 1-h at room temperature. After washing,
110 membranes were developed using LICOR Odyssey infrared imager (LICOR, Lincoln,
111 NE). Bands were quantified using ImageJ and normalized to GAPDH.

112

113 Flow cytometry: Flow cytometry of mouse atrial non-myocytes was done as previously
114 described in detail (7). Briefly, atrial non-myocytes were isolated after terminal PES
115 studies by mechanical and enzymatic digestion via Collagenase IV (320 U/mL; C4-22,
116 Sigma-Aldrich, St. Louis, MO), Dispase II (1 U/mL; D4693, Sigma-Aldrich, St. Louis, MO),
117 and DNase (60 U/mL; D45131VL, Sigma-Aldrich, St. Louis, MO) dissolved in phosphate-
118 buffered saline (PBS) supplemented with Ca^{2+} (0.9 mM) and Mg^{2+} (0.5 mM) at 37°C.
119 Quenching was achieved with a solution of 60 U/mL DNase and 2% fetal bovine serum
120 (FBS; TMS-016, Sigma-Aldrich, St. Louis, MO) in PBS without Ca^{2+} and Mg^{2+} . Cells were
121 filtered through a 70- μm filter and spun at 340 x g for 7 minutes at 4°C. Red blood lysis
122 was performed (catalog #00-4300-54, ThermoFisher Scientific, Waltham, MA) prior to
123 live/dead staining (catalog #L34959; ThermoFisher Scientific, Waltham, MA) at room
124 temperature for 15 minutes. Cells were resuspended in flow cytometry buffer (0.1%
125 gelatin, 0.05% NaN_3 in PBS without $\text{Ca}^{2+}/\text{Mg}^{2+}$) and incubated in Fc block (0.01 $\mu\text{g}/\mu\text{L}$;
126 catalog #553142, BD Biosciences, Franklin Lakes, NJ) for 5 minutes on ice. The following
127 flow antibodies were used: CD45-PE-Cy5 (0.06 $\mu\text{g}/\text{test}$; catalog #15-0451-81, clone 30-
128 F11, ThermoFisher Scientific, Waltham, MA), CD11b-PE (0.125 $\mu\text{g}/\text{test}$; catalog #12-
129 0112-81, clone M1/70, ThermoFisher Scientific, Waltham, MA), and Ly6G-FITC (0.5
130 $\mu\text{g}/\text{test}$; catalog #11-9668-82, clone 1A8-Ly6g, ThermoFisher Scientific, Waltham, MA).
131 Antibodies were added to the cell suspension and incubated at 4°C on a shaker for 45
132 minutes prior to imaging on a BD FACS Symphony. Data were analyzed using FlowJo
133 v10.10.0. Debris was gated out using forward and side scatter area, followed by gating
134 for singlets using forward scatter area and height and live cells using the live/dead stain.

135 Compensation was applied using singly-stained controls, and proper gating was
136 determined using fluorescence minus one (FMO) controls.

137

138 Human Pericardial Fluid Samples: Pericardial fluid was collected from patients with
139 pericardial drains placed for medical indications 24-36 hours after cardiac surgery.
140 Experimental protocols were approved by the local institutional review board (#H-46755).
141 Patients with prevalent infection were excluded. Pericardial fluid was spun for 5 minutes
142 at 800 x g at 4C. The supernatant (i.e., cell-free fraction) was used to assess MIF protein
143 levels by enzyme-linked immunosorbent assay (Proteintech #KE00248).

144

145 THP-1 cells: THP-1 cells were acquired as a generous gift from Dr. Huaizhu Wu (Baylor
146 College of Medicine, Houston, Texas). Cells were maintained in suspension in RPMI 1640
147 media supplemented with Penicillin/Streptomycin, 1M HEPES, 100 mM sodium pyruvate,
148 250 g/L D-glucose, and 0.05 nM beta-mercaptoethanol. Following treatment with
149 pericardial fluid or vehicle for 6-h, THP-1 monocyte suspension was spun at 500 x g for
150 5 minutes. For RNA isolation, the cell pellet was suspended in Trizol (15596, Life
151 technologies, Carlsbad, CA), and 500 µg of RNA was reverse transcribed by iScript
152 (1708841, Bio-Rad, Herclues, CA). The iTaq Universal SYBR Green Supermix (Fisher
153 Scientific, Waltham, MA) with 1 µM primer and cDNA (1:25 dilution) were used for real-
154 time quantitative polymerase chain reaction (RT-qPCR). The following RT-qPCR primers
155 were used: *GAPDH* (Forward: CCACTCCTCCACCTTTGAC, Reverse:
156 ACCCTGTTGCTGTAGCCA) and *IL1B* (Forward: AGCTGATGGCCCTAACAGA,
157 Reverse: TCGGAGATTCGTAGCTGGAT). The $\Delta\Delta CT$ method was used to calculate
158 relative gene expression normalized to GAPDH. For protein isolation blotting, pelleted

159 cells were suspended in RIPA lysis buffer, followed by western blotting (see above). The
160 following primary antibodies were used: phospho-Tyr705-STAT3 (Cell Signaling
161 Technology #9145, 1:1000), total STAT3 (Cell Signaling Technology #9139, 1:1000), and
162 GAPDH (Proteintech #60004, 1:5000).

163

164 Statistics: Statistics were performed using Prism version 10.1.1 (GraphPad, La Jolla, CA).

165 All data points represent individual biological replicates unless otherwise stated.

166 Continuous data are expressed as mean \pm standard error of the mean (SEM). The

167 D'Agostino-Pearson normality test was used to confirm normality. Two-sample t-tests or

168 one-way ANOVA were used for parametric continuous data, and Mann-Whitney test or

169 Kruskal-Wallis tests were used for non-parametric data. All two-sample t-tests were two-

170 tailed. Categorical variables were evaluated with Fisher's exact or chi-square tests.

171 Fisher's exact tests were used when expected counts were less than 5 in at least 80% of

172 groups. For multiple group comparison, 1-way ANOVA or Kruskal-Wallis followed by

173 Tukey or Dunn's post-hoc tests, respectively, were used to adjust for multiple testing with

174 $\alpha=0.05$. $P<0.05$ was considered statistically significant. Outliers were calculated by

175 the ROUT method with a false discovery rate of 1% (8). Power analyses were conducted

176 pre-hoc to determine sufficient sample size to detect statistically significant differences at

177 $\alpha=0.05$ with 80% power.

178

179

180 **REFERENCES**

- 181 1. Keefe JA, Navarro-Garcia JA, Ni L, Reilly S, Dobrev D, and Wehrens XHT. In-
182 depth characterization of a mouse model of postoperative atrial fibrillation. *J*
183 *Cardiovasc Aging*. 2022;2.
- 184 2. Winner M, Meier J, Zierow S, Rendon BE, Crichlow GV, Riggs R, et al. A novel,
185 macrophage migration inhibitory factor suicide substrate inhibits motility and
186 growth of lung cancer cells. *Cancer Res*. 2008;68(18):7253-7.
- 187 3. Li N, and Wehrens XH. Programmed electrical stimulation in mice. *J Vis Exp*.
188 2010(39):e1730.
- 189 4. Luo W, Wang Y, Zhang L, Ren P, Zhang C, Li Y, et al. Critical Role of Cytosolic
190 DNA and Its Sensing Adaptor STING in Aortic Degeneration, Dissection, and
191 Rupture. *Circulation*. 2020;141(1):42-66.
- 192 5. Li Y, Ren P, Dawson A, Vasquez HG, Ageedi W, Zhang C, et al. Single-Cell
193 Transcriptome Analysis Reveals Dynamic Cell Populations and Differential Gene
194 Expression Patterns in Control and Aneurysmal Human Aortic Tissue.
195 *Circulation*. 2020;142(14):1374-88.
- 196 6. Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, et al.
197 Inference and analysis of cell-cell communication using CellChat. *Nat Commun*.
198 2021;12(1):1088.
- 199 7. Keefe JA, Aguilar-Sanchez Y, Navarro-Garcia JA, Ong I, Li L, Paasche A, et al.
200 Macrophage-mediated interleukin-6 signaling drives ryanodine receptor-2
201 calcium leak in postoperative atrial fibrillation. *J Clin Invest*. 2025.

202 8. Motulsky HJ, and Brown RE. Detecting outliers when fitting data with nonlinear
203 regression - a new method based on robust nonlinear regression and the false
204 discovery rate. *BMC Bioinformatics*. 2006;7:123.


205

206 **SUPPLEMENTAL FIGURES**

207

208 **Figure S1. *Mif* is upregulated in *Acta2*⁺ AFBs in TAF versus sham mice. (A)** Dot plot
209 of top genes expressed by each AFB and macrophage cluster showing *Mif* to be enriched
210 in *Acta2*⁺ AFBs (FB4). **(B)** Cell-cell communication analyses using CellChat revealed MIF
211 to be a top differentially upregulated outgoing signaling pathway mediated by FB4. **(C)**
212 *Mif* expression was greater in AFBs and macrophages in TAF versus sham mice. Red
213 arrow denotes FB4. *Abbreviations:* AFB - atrial fibroblast, ANGPTL - angiopoietin-like
214 protein, COMP - complement, GAL - galectin, POSTN - periostin, SPP1 - secreted
215 phospho-protein 1, TAF - thoracotomy atrial fibrillation.

216



217

218 **Figure S2. MIF inhibition attenuates poAF duration in mice. (A)** Representative ECG

219 traces after burst pacing in sham (top), thoracotomy mouse treated with vehicle (middle),


220 and thoracotomy mouse treated with MIF inhibitor (bottom). **(B)** Quantification of poAF

221 duration (Kruskal-Wallis). Each dot in (B) denotes one mouse (N=10 Sh, N=17 Th, N=9

222 MIF-i). *Abbreviations:* ECG - electrocardiogram, MIF-i - MIF inhibitor, Sh - sham, Th -

223 thoracotomy, Veh - vehicle.

224




225

226

227 **Figure S3. MIF inhibition does not alter atrial PMN infiltration after thoracotomy.**


228 MIF was inhibited by 4-IPP given at 40 mg/kg/day from POD 0-2, followed by flow
229 cytometric staining of atrial non-myocytes for CD45, CD11b, and Ly6G. PMNs were
230 defined as CD45⁺/CD11b⁺/Ly6G⁺ cells. **(A-B)** TAF mice had trended toward greater atrial
231 PMN accumulation compared to sham mice whereas no differences were seen after MIF
232 inhibition. N=4 mice per group. *Abbreviations:* MIF - macrophage migration inhibitory
233 factor, PMN - polymorphonuclear neutrophil, POD - postoperative day, Sh - sham, TAF -
234 thoracotomy atrial fibrillation.

235



236

237 **Figure S4. MIF inhibition prevents PF-driven *IL1b* upregulation in THP-1**
 238 **monocytes.** Undifferentiated THP-1 monocytes were treated for 6-h with vehicle (blue),
 239 PF from SR patients (green), PF from poAF patients (red), and PF from poAF patients
 240 after 30-minute pretreatment with MIF-inhibitor 4-IPP at 100 μ M (yellow). RT-qPCR from
 241 treated THP-1 monocytes revealed significantly greater *IL1B* expression that was
 242 attenuated by MIF inhibition (1-way ANOVA). Each dot represents an individual well. N=4
 243 per group. *Abbreviations:* IL1B - interleukin-1 beta, PF - pericardial fluid, poAF -
 244 postoperative atrial fibrillation, SR - sinus rhythm, Veh - vehicle.



245

246

247 **SUPPLEMENTAL TABLES**

248

249 **Table S1. Demographic and clinical characteristics of cardiac surgery patients.**

	SR	poAF	P value	Test
Patients, n	6	11	N/A	N/A
Female/Male	4/2	4/7	0.335	Fisher's
Age, y (mean±SD)	53.3 ± 11.7	63.1 ± 7.6	0.106	T-test
CABG, n (%)	4 (67)	5 (45)	0.620	Fisher's
Aortic surgery, n (%)	1 (17)	3 (27)	>0.999	Fisher's
Valvular surgery, n (%)	1 (17)	2 (18)	>0.999	Fisher's
CABG + valvular, n (%)	0 (0)	1 (9)	>0.999	Fisher's
Beta blockers, n (%)	5 (83)	7 (64)	0.600	Fisher's
Lipid lowering, n (%)	4 (67)	7 (64)	>0.999	Fisher's
Aspirin, n (%)	4 (67)	3 (27)	0.162	Fisher's
DHP CCBs, n (%)	3 (50)	4 (36)	0.644	Fisher's
ACEi/ARB, n (%)	3 (50)	6 (55)	>0.999	Fisher's
Diuretics, n (%)	3 (50)	5 (45)	>0.999	Fisher's
Hypertension, n (%)	5 (83)	9 (82)	>0.999	Fisher's
Hyperlipidemia, n (%)	6 (100)	6 (55)	0.102	Fisher's
Diabetes mellitus, n (%)	4 (67)	6 (55)	>0.999	Fisher's
CAD, n (%)	5 (83)	6 (55)	0.333	Fisher's
Valvular disease, n (%)	2 (33)	3 (27)	>0.999	Fisher's

250

251 *Abbreviations:* ACEi - angiotensin converting enzyme inhibitor, ARB - angiotensin
 252 receptor blocker, CABG - coronary artery bypass grafting, CAD - coronary artery disease,
 253 CCBs - calcium channel blockers, DHP - dihydropyridine.